Skip to main content
. 2023 Sep 30;24:240. doi: 10.1186/s12931-023-02540-0

Table 2.

Patient characteristics and the statistical comparison between patients with the KIF15 missense variant and all other patients

KIF15-missense (N = 5) Others (N = 130) Sig
Background and comorbidities
 Female sex 0 (0%) 43 (33%) 0.177
 Male sex 5 (100%) 87 (67%) 0.177
 Family history of pulmonary fibrosis 0 (0%) 8 (6%) 1.000
 Smoking history 4 (80%) 82 (63%) 0.653
 Cancers 1 (20%) 32 (25%) 1.000
 BMI, kg/m2 34.0 (28.1–36.0) 27.8 (25.0–30.0) 0.028*
 Comorbidities, N 5.0 (2.0–7.5) 4.0 (2.0–6.0) 0.432
Treatment and prognosis
 Oxygen therapy 4 (80%) 39 (30%) 0.036*
 Antifibrotic treatment 4 (80%) 75 (58%) 0.402
 Lung transplantation 2 (40%) 13 (10%) 0.095
 Deceased 1 (20%) 61 (47%) 0.374
 Age at diagnosis, years 54.0 (36.5–69.5) 72.0 (65.8–75.3) 0.023*
 Age at death, years 61.2 (61.2–61.2) 79.0 (74.1–83.2) 0.032*
 Age at transplant, years 40.2 (30.9–40.2) 61.8 (53.6–65.2) 0.038*
 Age at death or transplant, years 49.4 (30.9–49.4) 76.8 (69.3–82.0)  < 0.001*
Symptoms
 Dyspnoea 3 (60%) 65 (50%) 1.000
 Cough 1 (20%) 68 (52%) 0.202
 Acute exacerbations 1 (20%) 33 (25%) 1.000
Laboratory findings
 Macrocytosis 1 (20%) 29 (23%) 1.000
 Thrombocytopenia 1 (20%) 17 (13%) 0.520
Radiological findings
 Right ventricular strain 1 (20%) 16 (12%) 0.495
 Emphysema 1 (20%) 31 (24%) 1.000
 Honeycombing 4 (80%) 104 (80%) 1.000
 Traction bronchiectasis 5 (100%) 127 (98%) 1.000
 Ground-glass opacity 2 (40%) 23 (18%) 0.231
Pulmonary function test findings
 FVC, L 3.35 (2.77–3.58) 2.95 (2.40–3.71) 0.578
 FVC, % predicted 59.0 (51.5–90.0) 81.0 (68.0–93.0) 0.128
 FEV1, L 2.73 (2.27–2.76) 2.36 (1.96–3.04) 0.562
 FEV1, % predicted 66.0 (55.0–84.0) 82.0 (73.0–95.0) 0.086
 DLCO, % predicted 52.0 (37.0–64.5) 59.0 (50.5–69.5) 0.188

Bold values are statistically significant p < 0.05